<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35027728</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>210</StartPage><EndPage>216</EndPage><MedlinePgn>210-216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41590-021-01113-x</ELocationID><Abstract><AbstractText>A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we studied individuals with LC compared to age- and gender-matched recovered individuals without LC, unexposed donors and individuals infected with other coronaviruses. Patients with LC had highly activated innate immune cells, lacked naive T and B cells and showed elevated expression of type I IFN (IFN-&#x3b2;) and type III IFN (IFN-&#x3bb;1) that remained persistently high at 8 months after infection. Using a log-linear classification model, we defined an optimal set of analytes that had the strongest association with LC among the 28 analytes measured. Combinations of the inflammatory mediators IFN-&#x3b2;, PTX3, IFN-&#x3b3;, IFN-&#x3bb;2/3 and IL-6 associated with LC with 78.5-81.6% accuracy. This work defines immunological parameters associated with LC and suggests future opportunities for prevention and treatment.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Phetsouphanh</LastName><ForeName>Chansavath</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6617-5995</Identifier><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. cphetsouphanh@kirby.unsw.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Darley</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-9721-101X</Identifier><AffiliationInfo><Affiliation>St Vincent's Hospital, Darlinghurst, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Daniel B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howe</LastName><ForeName>Annett</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munier</LastName><ForeName>C Mee Ling</ForeName><Initials>CML</Initials><Identifier Source="ORCID">0000-0002-6419-142X</Identifier><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Sheila K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juno</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-9072-1017</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burrell</LastName><ForeName>Louise M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0003-1863-7539</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-8539-4891</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne Sexual Health Centre, Infectious Diseases Department, Alfred Health, Central Clinical School, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dore</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St Vincent's Hospital, Darlinghurst, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kelleher</LastName><ForeName>Anthony D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0002-0009-3337</Identifier><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. akelleher@kirby.unsw.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St Vincent's Hospital, Darlinghurst, New South Wales, Australia. akelleher@kirby.unsw.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Matthews</LastName><ForeName>Gail V</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. gmatthews@kirby.unsw.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St Vincent's Hospital, Darlinghurst, New South Wales, Australia. gmatthews@kirby.unsw.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1902854</GrantID><Agency>NSF | Directorate for Mathematical &amp;amp; Physical Sciences | Division of Mathematical Sciences (DMS)</Agency><Country/></Grant><Grant><GrantID>1055214</GrantID><Agency>Department of Health | National Health and Medical Research Council (NHMRC)</Agency><Country/></Grant><Grant><GrantID>1123673</GrantID><Agency>Department of Health | National Health and Medical Research Council (NHMRC)</Agency><Country/></Grant><Grant><GrantID>1136322</GrantID><Agency>Department of Health | National Health and Medical Research Council (NHMRC)</Agency><Country/></Grant><Grant><GrantID>1149990</GrantID><Agency>Department of Health | National Health and Medical Research Council (NHMRC)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Front Immunol. 2024 Jan 04;14:1329026. doi: 10.3389/fimmu.2023.1329026</RefSource><PMID Version="1">38250080</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pii">10.1038/s41590-021-01113-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626&#x2013;631 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId><ArticleId IdType="pmc">7611399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. &amp; Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324, 782&#x2013;793 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho, T., Krammer, F. &amp; Iwasaki, A. The first 12 months of COVID-19: a timeline of immunological insights. Nat. Rev. Immunol. 21, 245&#x2013;256 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00522-1</ArticleId><ArticleId IdType="pubmed">33723416</ArticleId><ArticleId IdType="pmc">7958099</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727&#x2013;733 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId><ArticleId IdType="pmc">7092803</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, M. J., et al. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. Preprint at medRxiv https://doi.org/10.1101/2021.03.11.21252311 (2021).</Citation></Reference><Reference><Citation>Lam, M. H. et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch. Intern. Med. 169, 2142&#x2013;2147 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2009.384</ArticleId><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed, H. et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J. Rehabil. Med 52, jrm00063 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin, S. J. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J. Med Virol. 93, 1013&#x2013;1022 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Darley, D. R. et al. Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection. Med J. Aust. 214, 279&#x2013;280 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja2.50963</ArticleId><ArticleId IdType="pubmed">33657671</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortinovis, M., Perico, N. &amp; Remuzzi, G. Long-term follow-up of recovered patients with COVID-19. Lancet 397, 173&#x2013;175 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00039-8</ArticleId><ArticleId IdType="pubmed">33428868</ArticleId><ArticleId IdType="pmc">7833833</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 397, 220&#x2013;232 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId><ArticleId IdType="pmc">7833295</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre, C. H., et al. Anosmia and other SARS-CoV-2 positive test-associated symptoms, across three national, digital surveillance platforms as the COVID-19 pandemic and response unfolded: an observation study. Preprint at medRxiv https://doi.org/10.1101/2020.12.15.20248096 (2020).</Citation></Reference><Reference><Citation>Tenforde, M. W. et al. Characteristics of adult outpatients and inpatients with COVID-19 - 11 academic medical centers, United States, March-May 2020. MMWR Morb. Mortal. Wkly Rep. 69, 841&#x2013;846 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6926e3</ArticleId><ArticleId IdType="pubmed">32614810</ArticleId><ArticleId IdType="pmc">7332092</ArticleId></ArticleIdList></Reference><Reference><Citation>Darley, D. et al. Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort. ERJ Open Res. 7, 00384&#x2013;2021 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00384-2021</ArticleId><ArticleId IdType="pubmed">34725634</ArticleId><ArticleId IdType="pmc">8504133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.Sci. Rep. 11, 16144 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId><ArticleId IdType="pmc">8352980</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, S. K. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences.Eur. Respir. J. 57, 2003730 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03730-2020</ArticleId><ArticleId IdType="pubmed">33479113</ArticleId><ArticleId IdType="pmc">7830336</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn, P. K. Log-linear models. In Encyclopedia of Social Measurement (Ed. Kempf-Leonard, K.) 585&#x2013;589 (Elsevier, 2005).</Citation></Reference><Reference><Citation>Broggi, A. et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science 369, 706&#x2013;712 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32527925</ArticleId><ArticleId IdType="pmc">7292499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718&#x2013;724 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId><ArticleId IdType="pmc">7402632</ArticleId></ArticleIdList></Reference><Reference><Citation>Major, J. et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 369, 712&#x2013;717 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc2061</ArticleId><ArticleId IdType="pubmed">32527928</ArticleId><ArticleId IdType="pmc">7292500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueland, T. et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J. Allergy Clin. Immunol. 147, 92&#x2013;98 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.09.007</ArticleId><ArticleId IdType="pubmed">32971109</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271&#x2013;280 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId><ArticleId IdType="pmc">7102627</ArticleId></ArticleIdList></Reference><Reference><Citation>Portela Sousa, C. &amp; Brites, C. Immune response in SARS-CoV-2 infection: the role of interferons type I and type III. Braz. J. Infect. Dis. 24, 428&#x2013;433 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjid.2020.07.011</ArticleId><ArticleId IdType="pubmed">32866437</ArticleId><ArticleId IdType="pmc">7448817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly, A. et al. Immune cell profiling of IFN-lambda response shows pDCs express highest level of IFN-lambdaR1 and are directly responsive via the JAK-STAT pathway. J. Interferon Cytokine Res. 36, 671&#x2013;680 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2015.0169</ArticleId><ArticleId IdType="pubmed">27617757</ArticleId><ArticleId IdType="pmc">5165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Norata, G. D. et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120, 699&#x2013;708 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.806547</ArticleId><ArticleId IdType="pubmed">19667236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura, S. et al. Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction. Circ. J. 78, 159&#x2013;169 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-13-0329</ArticleId><ArticleId IdType="pubmed">24132243</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunetta, E. et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat. Immunol. 22, 19&#x2013;24 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00832-x</ArticleId><ArticleId IdType="pubmed">33208929</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, T., Narazaki, M. &amp; Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016295</ArticleId><ArticleId IdType="pubmed">25190079</ArticleId><ArticleId IdType="pmc">4176007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagunas-Rangel, F. A. &amp; Chavez-Valencia, V. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients. J. Med Virol. 92, 1789&#x2013;1790 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25900</ArticleId><ArticleId IdType="pubmed">32297995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Z. et al. COVID-19 severity correlates with weaker T-cell immunity, hypercytokinemia, and lung epithelium injury. Am. J. Respir. Crit. Care Med 202, 606&#x2013;610 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202005-1701LE</ArticleId><ArticleId IdType="pubmed">32608999</ArticleId><ArticleId IdType="pmc">7427397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. Science 369, 6508 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos, M. et al. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep. Med 2, 100208 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100208</ArticleId><ArticleId IdType="pubmed">33564749</ArticleId><ArticleId IdType="pmc">7862905</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskinen, P., Ronni, T., Matikainen, S., Lehtonen, A. &amp; Julkunen, I. Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells. Immunology 91, 421&#x2013;429 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2567.1997.00258.x</ArticleId><ArticleId IdType="pubmed">9301532</ArticleId><ArticleId IdType="pmc">1364012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregorova, M. et al. Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. Elife 9, e63430 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.63430</ArticleId><ArticleId IdType="pubmed">33331820</ArticleId><ArticleId IdType="pmc">7775105</ArticleId></ArticleIdList></Reference><Reference><Citation>Habel, J. R. et al. Suboptimal SARS-CoV-2-specific CD8<sup>+</sup> T cell response associated with the prominent HLA-A*02:01 phenotype. Proc. Natl Acad. Sci. USA 117, 24384&#x2013;24391 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2015486117</ArticleId><ArticleId IdType="pubmed">32913053</ArticleId><ArticleId IdType="pmc">7533701</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh, C. et al. Maintenance of functional CD57<sup>+</sup> cytolytic CD4<sup>+</sup> T Cells in HIV+ Elite Controllers. Front. Immunol. 10, 1844 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01844</ArticleId><ArticleId IdType="pubmed">31440240</ArticleId><ArticleId IdType="pmc">6694780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew, R. A. et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp. Physiol. 93, 685&#x2013;693 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/expphysiol.2007.040352</ArticleId><ArticleId IdType="pubmed">18223027</ArticleId><ArticleId IdType="pmc">7197901</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>